Analyses suggest squamous and nonsquamous tumors differ in immunobiology and may respond differently to the addition of LAG-3 inhibitors to PD-1–based therapy.
The post Histologic Subtype May Inform Immunotherapy Strategy in mNSCLC Without Targetable Mutations first appeared on Physician’s Weekly.
